The drug likely won't be dosed longer 1x/day than 7-14 days, so cumulative tox is unlikely to be much of a problem beyond the 10 doses we've already seen. The big test for both side effects is to see if they worsen in actual patients. Remember, the drug hasn't been in infected patients yet.
This is a good question. Again, while this looks really promising there is no data in real patients yet. We initiated formal coverage on the company back in January. The biggest issue is that the programs are very early with little data in actual patients for either drug, but especially the antibiotic. Patience and patients, as a wise man I know once said, will reveal whether they indeed have something here.
Unless otherwise indicated, this is the personal viewpoint of David Miller and not necessarily that of Biotech Stock Research, LLC. We're on Twitter at BiotechStockRsr
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.